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Available online 16 July 2016Novel silver(I) complexes of coumarin oxyacetate ligands and their phenanthroline adducts have been prepared
and characterised by microanalytical data and spectroscopic techniques (IR, 1H, 13C NMR, UV–Vis). The crystal
structure of one Ag(I) complex was determined by X-ray diffraction analysis. The experimental spectroscopic
data have been interpreted on the basis of molecular structure modeling and subsequent spectra simulation
with density functional theory method. The binding modes of the coumarins and phenanthroline ligands
(monodentate, bidentate, bridging) to Ag(I) have been theoreticallymodelled and discussed as to themost prob-
able ligand binding in the series of complexes studied. The antimicrobial and antifungal activities have been de-
termined and the complexes were found to have mostly moderate antibacterial activity but some of the
phenanthroline adducts were found to have antifungal activity against the clinically important fungus C. albicans,
comparable to that of the commercial agents, Amphotericin B and Ketoconazole. Preliminary investigations into
the possiblemechanism of action of the silver complexes indicated that they did not interactwith DNA via nucle-
ase activity or intercalation but the ability to act as a superoxide dismutase mimetic may be related to their an-
timicrobial activity.
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Several multidrug resistant (MDR) strains of bacteria such as fluoro-
quinolone- and carbapenem-resistant Pseudomonas aeruginosa and van-
comycin-resistant Staphylococcus aureus have emerged as a result of
the ability of microbes to adapt to continuously changing environments
[1–5]. Treatment of resistant bacterial strains has become a major prob-
lem with rising mortality rates and extended hospitalisation for patients
translating into ever increasing health care costs,with a report in 2015 es-
timating that cost to the EU to be at 1.5 billion euro annually [6]. Common
pathogens such as S. aureus are responsible for harmful infections includ-
ing mastitis, upper respiratory complications, bacteraemia, pneumonia,
skin and soft tissue infections. In particular, S. aureus causes a diversity
of infections, from skin infections to disseminated systemic infections
leading to organ failure and death [3,7,8]. These pathogens can easily beaven), ivelina@svr.igic.bas.bgtransmitted betweenpatients andhave become resistant to different clas-
ses of antibiotic drugs, e.g., some strains of methicillin resistant S. aureus
(MRSA) are often resistant to several antibiotics, including penicillins
and cephalosporins [9–11]. In Western Europe a review of intensive
care unit infections found that P. aeruginosawas identified as one of the
most common organisms, constituting nearly a third (29%) of all Gram-
negative isolates, and was present in 17% of all positive cultures [12]. In
addition, in 2013, theCentre forDisease Control andPreventionpublished
a report outlining the threat posed byMDRGram-negative pathogens and
highlighted that the world is currently running out of drugs to treat sev-
eral Gram-negative infections [13].
The number of incidences of serious fungal infections is also increasing
dramatically andwith it a rise in resistance to antifungal treatment and its
associated healthcare costs. Individuals with weakened immune systems
are more likely to get fungal infections. These individuals are either vic-
tims of Acquired Immune Deficiency Syndrome (AIDS) or cancer patients
receiving aggressive chemotherapy, or following organ transplantation
and long hospitalisation [14]. Candida albicans is a causal agent of oppor-
tunistic oral and genital infections in humans. It can also form biofilms on
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ogen causing systemic fungal infections aswell as hospital-acquired infec-
tions and has become an important clinical problem [15]. It is responsible
for several infections in humans including deepmycoses, bloodstream in-
fections, mouth, skin, vaginal and human immunodeficiency virus (HIV)-
related infections as well as Candidiasis [16,17]. Oral infections can be
treated with drugs such as Fluconazole and Ketoconazole or typically
with polyene-based Amphotericin B and systemic fungal infections can
be treated with intravenous administration of Amphotericin B or
caspofungin. However, azole-resistant strains of Candida albicans have
emerged and these have created problems for administering azole-
based treatments [18]. In addition, some of these drugs, such as
Amphotericin B are nephrotoxic and damage host cells [14]. The increas-
ing incidence of antifungal resistance in Candida spp. reflects the exten-
sive and escalating use of newer broad-spectrum antifungal agents and
thus presents a serious threat to patients worldwide [19,20].
Generally, silver(I) complexes are known to possess significant anti-
bacterial activities against Gram-positive and Gram-negative bacteria
and have shown excellent activity against C. albicans [21–26]. In recent
reviews the applications of silver(I) metallodrugs and current silver-
based antimicrobial therapeutics which are commercially available are
discussed in detail [27,28]. More recently the synthesis of silver/amino
acid biopolymer hydrogels as mouldable wound dressings have also
been reported [29–31]. Thus the role of silver(I), acting as a free ion,
or in compounds such as sulfadiazine or as a hydrogel or nanoparticle
has been well established. We have been interested in silver(I) com-
plexes of coumarins for a number of years and they have shown activity
against a number of antibiotic and antifungal resistant strains. Couma-
rins are a class of compounds which occur naturally in many plants
and have revealed a diverse array of pharmacological properties [32].
Previous studies have shown that silver(I) complexes of coumarin-3-
carboxylates and coumarin-4-carboxylates have excellent activity
against MRSA and P. aeruginosa respectively [21,33,34]. Exposure of S.
aureus to silver nitrate has been shown to lead to a transient increase
in superoxide dismutase (SOD) activity and catalase activity which
may indicate that the silver compound induces oxidative stress in the
cell [35]. A more recent paper has shown that silver enhances antibiotic
activity against Gram-negative bacteria by interferingwith cellular pro-
cesses and sensitizing the cells towards current antibiotics [36]. The au-
thors reported that the presence of silver appeared to induce oxidative
stress in treated cells. We have recently reported a series of water-solu-
ble and photo-stable silver(I) dicarboyxlate complexes with excellent
antimicrobial activity and anticancer activity. Interestingly these com-
plexes appeared to have a different mechanism of action to other
silver(I) compounds in that they did not induce deoxyribonucleic acid
(DNA) damage or reactive oxygen species (ROS) generation and in
fact seemed to act as antioxidants in the systems studied, significantly
reducing superoxide and hydrogen peroxide induced oxidative stress
in the yeast S. cerevisiae [37].
The results of our previous studies have also shown that the mode of
antifungal action for the silver(I) coumarin-based complexes was based
on their interference with respiration in the fungal cells, resulting in re-
duced ergosterol synthesis and cytochrome production [38]. This mode
of action is different to conventional azole and polyene drugs (which
bind to ergosterol or block ergosterol biosynthesis, respectively) and
thus they looked like promising candidates for new antifungal treatment.
Subsequent studies on related phenanthroline adducts of these com-
plexes and other related phenanthroline silver(I) adducts showed that
their mechanism of action was based on disruption of mitochondrial
function also [39].
In all of the coumarin complexes previously studied, their solubility
was of concern to us and in many studies the complexes were tested as
suspensions. In an attempt to improve the activity of coumarin carboxyl-
ate silver(I) complexes by means of higher solubility and better pharma-
cological properties we succeeded in isolating a series of Ag(I) complexes
with coumarin oxyacetate ligands in the 3-, 4-, as well as the 6- and 7-positions on the aromatic ring. In addition, their 1,10-phenanthroline
(phen) adducts were prepared as the solubility and biological activities
of the complexes are also known to increase significantly upon adduct
formation with phen [40–44]. The novel Ag(I) complexes were
characterised by experimental physico-chemical and spectroscopic (IR,
1H, 13C NMR and UV–Vis) studies in solid state and in solution and by
X-ray diffraction analysis. In addition, density functional theory (DFT)
modeling of the compounds studiedwas performed to support or predict
the metal-ligand binding mode in the coumarin oxyacetate-derived
silver(I) complexes and their phen adducts based on the good agreement
between the experimental and calculated spectroscopic data.2. Experimental
2.1. Reagents and instruments
Chemicals and solvents were purchased from Sigma-Aldrich Co. (Dor-
set, UK) and used without further purification. Melting points were re-
corded on a Stuart Scientific SMP-1 apparatus (up to 300 °C). Thin layer
chromatographic (TLC) studywas carried out on Silica gel 60F254 alumin-
ium-backed plates using a pre-saturated elution tank. The compounds
were detected under ultraviolet light and stained using iodine crystals
in a closed chamber. Infrared spectra of solids (as a dispersion in KBr
disc)were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer op-
erating at a resolution of 2 cm−1 in the 4000–400 cm−1 region. The
Bruker Biospin 300 and 500MHz FT-NMR spectrometerswere used to re-
cord 1HNMR spectra (−5 to 15 ppmwith a resolution of 0.18Hz) and 13C
NMR spectra (−33 to 233 ppmwith a resolution of 2.40 Hz) as solutions
in dimethyl sulfoxide (DMSO-d6) using tetramethylsilane (TMS) as the
internal reference standard. The signal assignments were made using
standard techniques including distortionless enhancement by polariza-
tion transfer (DEPT), homonuclear correlation spectra (COSY) and CH-
Shift. Where necessary, Heteronuclear Single Quantum Correlation
(HSQC), Heteronuclear Multiple Bond Correlation (HMBC) and Nuclear
Overhauser effect spectroscopy (NOESY) experimentswere also run to fa-
cilitate peak assignments. Microanalytical data were provided by the Mi-
croanalytical Laboratory, Department of Chemistry, University College
Dublin, Belfield, Dublin-4, Ireland, using a PerkinElmer CHN analyser. Sil-
ver content was determined using atomic absorption spectroscopy on a
PerkinElmer 460AAS instrument. All samples were analysed in triplicate.
UV–Vis spectra of the complexes and their corresponding ligands were
recorded on a PG Instruments T80 UV/Vis spectrophotometer in DMSO
solvent (260–800 nm). The molar conductivity of the complexes and
their corresponding ligands was measured on an EUTOH INSTRUMENTS
Cyberscan-500 digital conductometer, using 4 mM solution of com-
pounds in DMSO at 25 °C. Themetal andwater contents of the complexes
were determined by using thermogravimetric technique. Thermogravi-
metric analysis (TGA) was carried out in the temperature range from 25
to 800 °C in a nitrogen atmosphere using TA Instrument's Q50 Thermo-
gravimetric analyser. The experimental conditions were: platinum
weighing pan, nitrogen atmosphere with a 60 ml/min flow rate and a
heating rate of 10 °C/min.
A single crystalwas coated in Paratone-N heavy oil thenmounted on
a Hampton Research Cryoloop and placed in a cold stream of nitrogen
gas (100 K) on a Bruker Nonius ×8 Apex2 CCD diffractometer running
the Apex2 software (Bruker 2011). Data collection consisted of, on aver-
age, 3000 frames from a combination of phi and omega scans. After unit
cell determination, intensity data were integrated using SAINT then
scaledwith TWINABS [45] (Ag(I) complex 33was treated as a 3 compo-
nent crystal) before Space group determination with XPREP [46]. The
SHELXTL suites of programs [46,47] were used for structure solution
and OLEX2 for figures and refinement [48]. All non-hydrogen atoms
were refined anisotropically but significant numberswere subject to re-
straints. The water molecules were treated as rigid bodies to find initial
suitable H atom positions where close H┄H contacts were avoided and
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were fixed (using AFIX 1).
2.2. Syntheses
2.2.1. Synthesis of 2-(2-oxo-2H-chromen-substituted-yl)oxy acetic acid-
based ligands (12−22)
Firstly, the ethyl 2-(2-oxo-2H-chromen-substituted-yl)oxy acetate
derivatives (1−11) were prepared by reaction of the appropriate
substituted monohydroxy coumarin with ethyl 2-bromoacetate. The
synthetic methodology, together with the analytical and spectroscopic
data is given in SchemeS1, Table S1-S4 and Section S1 in Supplementary
material. Then, the compounds obtained (1–11) were used as precur-
sors for the synthesis of 2-(2-oxo-2H-chromen-substituted-
yl)oxy acetic acids (12–22) (Table 1) using the synthetic methodology
described in Section S2. The analytical and IR spectral data for all the
2-(2-oxo-2H-chromen-substituted-yl)oxy acetic acid derivatives syn-
thesized are shown in Table S5 (Supplementary material). Full 1H and
13C NMR spectral data are given in Tables S6 and S7, respectively (Sup-
plementary material). The atom numbering system used for the assign-
ment of the 1H and 13C NMR spectra is given in Table 1.
2.2.2. Synthesis of silver(I) complexes of 2-(2-oxo-2H-chromen-substitut-
ed-yl)oxy acetic acids (23−33)
A literature method was adopted for the synthesis of these com-
plexes [21] and full synthetic details are given in Section S3 in Supple-
mentary material. Selected bond lengths and bond angles obtainedTable 1
Substituents, their positions, atom number assignment for 1H and 13C NMR spectra and abbrev
IUPAC name of the compound/abbreviation (number)
2-[(2-Oxo-2H-chromen-3-yl)oxy]acetic acid/C-3oxy-acetH (12)
2-[(2-Oxo-2H-chromen-4-yl)oxy]acetic acid/C-4oxy-acetH (13)
2-[(6-Chloro-2-oxo-2H-chromen-4-yl)oxy]acetic acid/6Cl-C-4oxy-acetH (14)
2-[(2-Oxo-2H-chromen-6-yl)oxy]acetic acid/C-6oxy-acetH (15)
2-[(4-Methyl-2-oxo-2H-chromen-6-yl)oxy]acetic acid/4Me-C-6oxy-acetH (16)
2-[(2-Oxo-2H-chromen-7-yl)oxy]acetic acid/C-7oxy-acetH (17)
2-[(4-Methyl-2-oxo-2H-chromen-7-yl)oxy]acetic acid/4Me-C-7oxy-acetH (18)
2-[(3,4,8-Trimethyl-2-oxo-2H-chromen-7-yl)oxy]acetic acid/3,4,8-triMe-C-7oxy-acetH (1
2-[(3-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]acetic acid/3Cl-4Me-C-7oxy-acetH (2
2-{[4-(Trifluoromethyl)-2-oxo-2H-chromen-7-yl]oxy}acetic acid/4CF3-C-7oxy-acetH (21)
2-[(8-Acetyl-2-oxo-2H-chromen-7-yl)oxy]acetic acid/8acetyl-C-7oxy-acetH (22)
CF3⁎/CH3⁎= assigned 15 to carbon and its protons. CH3″= assigned 16 to carbon and its prot
.
Atoms and substituents position numbering scheme for coumarin moiety and 1,10-phenanthrfrom crystal structure determination of complex 33 are presented in
Table 2. Full analytical and IR, 1H, 13C NMR and UV–Vis spectroscopic
data are presented in Section S3, Supplementary material with selected
data for representative complexes given in Table S8 and Tables 3-6.
2.2.3. Synthesis of 1,10-phenanthroline adducts of silver(I) complexes of 2-
(2-oxo-2H-chromen-substituted-yl)oxy acetic acid-based ligands (34–44)
A literature method was adopted for the synthesis of these adducts
[21]. All of the following reactions were carried out under dark condi-
tions to obtain suitable complexes for structure elucidation studies.
The experimental data recorded for phen adducts (34–44) are given in
Section S4 in Supplementarymaterial with selected data for representa-
tive complexes given in Tables 3-6.
2.3. Computational details
Molecular structures, vibrational (IR), NMR and absorption spectra
calculations of the model Ag(I) complexes: Ag2(C-3oxy-acet)2, Ag(C-
3oxy-acet)phen2, Ag2(8acetyl-C-7oxy-acet)2 and Ag(8acetyl-C-7oxy-
acet)phen2 were carried outwith DFT/TDDFTmethod using Gaussian09
program [49]. A bidentate oxylate bridging binding was simulated in
Ag2(L)2 models as it was found in the X-ray determined structure of
[Ag(8acetyl-C-7oxy-acet)] (33). Following the suggested formula for
Ag(I)-phen adducts, a possible monodentate oxalate bonding of the
oxy-acetate coumarin and N,N-bidentate bonding of the two phen li-
gands were simulated for Ag(C-3oxy-acet)phen2 and Ag(8acetyl-C-
7oxy-acet)phen2 structures. For comparison, the correspondingiations for 2-(2-oxo-2H-chromen-substituted-yl)oxy acetic acid ligands (12–22).
-R3 -R4 -R5 -R6 -R7 -R8
OCH2COOH H H H H H
H OCH2COOH H H H H
H OCH2COOH H Cl H H
H H H OCH2COOH H H
H CH3⁎ H OCH2COOH H H
H H H H OCH2COOH H
H CH3⁎ H H OCH2COOH H
9) CH3⁎ CH3″ H H OCH2COOH CH3‴
0) Cl CH3⁎ H H OCH2COOH H
H CF3⁎ H H OCH2COOH H
H H H H OCH2COOH CH3CO
ons. CH3‴ = assigned 17 to carbon and its protons.
oline (R_H).
Table 2
Selected bond lengths (Å) and bond angles (°) of [Ag(8acetyl-C-7oxy-acet)] (33) obtained from X-ray crystallographic analysis.
Geometric parameters (Å, °) for (ag1)
Ag1—Ag2 2.7490 (16) O14—Ag1i 2.200 (9)
Ag1—O14i 2.200 (9) O14—Ag2iv 2.353 (8)
Ag1—O16ii 2.497 (11) C15—C16 1.49 (2)
Ag1—O28 2.126 (9) C15—O16 1.207 (17)
Ag1—O29iii 2.384 (9) C15—O17 1.47 (2)
Ag2—O2 2.500 (10) O15—Ag2i 2.158 (9)
Ag2—O14iv 2.353 (8) C16—C17 1.41 (2)
Ag2—O15i 2.158 (9) C16—C25 1.358 (19)
Ag2—O29 2.206 (9) O16—Ag1ii 2.497 (11)
O14i—Ag1—Ag2 76.4 (2) O14i—Ag1—O16ii 86.7 (4)
O14i—Ag1—O29iii 81.8 (3) O16ii—Ag1—Ag2 104.9 (2)
O28—Ag1—Ag2 88.3 (2) O28—Ag1—O14i 162.6 (3)
O28—Ag1—O16ii 105.6 (4) O28—Ag1—O29iii 107.6 (4)
O29iii—Ag1—Ag2 145.9 (2) O29iii—Ag1—O16ii 99.5 (3)
O2—Ag2—Ag1 121.6 (2) O14iv—Ag2—Ag1 149.3 (2)
O14iv—Ag2—O2 83.8 (3) O15i—Ag2—Ag1 85.8 (2)
O15i—Ag2—O2 105.1 (4) O15i—Ag2—O14iv 105.2 (3)
O15i—Ag2—O29 157.0 (4) O29—Ag2—Ag1 77.7 (2)
O29—Ag2—O2 97.2 (4) O29—Ag2—O14iv 82.4 (3)
Ag1i—O14—Ag2iv 98.2 (3) Ag2—O29—Ag1v 97.1 (4)
Note: symmetry transformations used to generate equivalent atoms: (i)−x+ 2,−y+ 2,−z+ 1; (ii) x− 1, y, z; (iii)−x+ 1,−y+ 1,−z+ 1; (iv) -x+ 3,−y+ 2,−z+ 1;
(v) x+ 1, y, z.
Hydrogen-bond geometry (Å) for (ag1)
D—H⋯A D—H H⋯A D⋯A D—H⋯A
C7—H7⋯O19vi 0.95 2.67 3.47 (2) 143
C9—H9⋯O19vi 0.95 2.64 3.46 (2) 144
C20—H20⋯O5vii 0.95 2.28 3.23 (2) 177
C23—H23⋯O1W 0.95 2.47 3.285 (14) 144
C23—H23⋯O2W 0.95 2.62 3.494 (16) 153
O1W—H1WA⋯O2Wv 0.87 1.98 2.793 154.6
O1W—H1WB⋯O2W 0.87 1.99 2.611 127.4
Symmetry codes: (v) x+ 1, y, z; (vi) x+ 1, y+ 1, z; (vii)−x,−y+ 1,−z+ 2.
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acetH (12) and 8acetyl-C-7oxy-acetH (22). Split valence plus polariza-
tion basis set 6-31G(d) was applied for the main group elements: for
hydrogen atoms it is (4s)/[2s], for carbon and oxygen atoms it is
(10s4p1d)/[3s2p1d]. To give a better description of the wave functions
in the intermolecular region and hence to improve the estimation of the
Ag(I) – coumarin ligand interactions, diffuse functions were added to
the standard basis set (one s and one p set) for all O atoms as well as
for the two acetoxy carbon, C11 and C12 atoms (see a scheme under
Table 1). The combined basis set is denoted CB1. The computations
using CB1 basis set were carried out with the Lee, Yang, and Parr correla-
tion functional (LYP) [50] combined with Becke's three parameters ex-
change functional (B3) [51]. The adequacy of B3LYP method for
prediction of conformational behaviour, geometry parameters and vibra-
tional spectra of coumarin derivatives and their metal complexes was
proven in our previous investigations [52,53]. The Ag(I) ion was calculat-
ed with the effective core potential (ECP) optimized by the Stuttgart–
Dresden group [54,55]. The small quasi-relativistic pseudopotential,
ECP28MWB, was used for Ag(I) in combination with its optimized va-
lence basis set (8s7p6d)/[6s5p3d]. The small core (RECPs) for the Ag(I)
centre considers explicitly 19 valence electrons (4s24p64d105s1), whereas
28 core electrons ([Ar]3d10 shells) are replaced by the pseudopotential.
Full geometry optimizations of all themolecular systemswere carried
out without symmetry constraint. The minima on the potential energy
surfaces were qualified by the absence of negative eigenvalues in the di-
agonalized Hessian matrix, giving imaginary normal vibrational mode.
The projection of the internal coordinates onto each normal mode in
terms of percentage relative weights was computed as implemented in
Gaussian09. Each normal mode is described on the basis of the largest
percentage value of the total displacement vector magnitude. In addition,
the vibrational modes have been analysed by visual inspection of the
modes animated using the ChemCraft program [56]. The 1H and 13CNMR chemical shift calculations of the model compounds 12, 22, 23, 33,
and 34were performed in DMSO at B3LYP/6–31 + G(d,p) level. The ab-
solute isotropic magnetic shielding constants (σi) were used to obtain
the chemical shifts (δi = σTMS − σi) for C and H atoms by referring to
the standard compound, TMS. The UV–Vis absorption spectra of the
ligands and their Ag(I) complexes were simulated in the region 200–
400nmbymeans of vertical excitation energy calculations (of singlet excit-
ed states) in DMSO using TDDFT method and B3LYP/CB1 level. NMR and
UV–Vis spectra calculations in DMSO were performed for the optimized
geometries in the same solvent. A non-equilibrium implementation of the
Polarisable ContinuumModel (PCM) using the integral equation formalism
variant (IEFPCM) was applied to simulate the solvent [57–59].
2.4. Antimicrobial studies
The ligands (12–22), Ag(I) complexes (23–33), phenanthroline ad-
ducts (34–44) and commercially available drugs, gentamycin and van-
comycin, were screened for their antimicrobial activity. S. aureus
(NCIMB 12702)was obtained from the National Collection of Industrial,
Marine and Food.MRSA strain ATCC4300 and P. aeruginosa strain ATCC
27853 were obtained from the American Type Culture Collection. P.
aeruginosa were cultured in Luria Bertani (LB) broth (Sigma) while
MRSA was cultured in nutrient broth. Bacteria were stored in broth
with 20% glycerol at −80 °C and passaged twice on agar plate (LB
agar, Trypticase Soy agar (TSA) or nutrient agar respectively) before
being used in an experiment. MIC50 were determined by broth
microdilution. Stock solutions of each compound to be tested were pre-
pared in DMSO and serially diluted in triplicate using broth (100 μl/
well) at a concentration range of 0.195–200 μM on microtitre plates,
after which the final concentration of DMSO in the cell suspension
was not N1%. Overnight cultures (10 ml) of bacterial strains were inoc-
ulated in broth (100 ml) and incubated at 37 °C with agitation, optical
Table 3
Selected experimental and calculated* IR frequencies (ν, cm−1) of ligands and their silver(I) complexes and phen adducts.
Compound vC\\H vC_Ocoumarin/vC_Oacid vasym(OCO) vsym(OCO) Δv(OCO)
C-3oxy-acetH (12) 3052 v, 2997 vw 1713 vs/1736 s – – –
(1711/1761)calc*
[Ag(C-3oxy-acet)] (23) 3055 v, 2980 vw 1721 vs (1718)calc 1584 s 1402 m 182
(1566)calc (1392)calc (174)calc
[Ag(C-3oxy-acet)phen2] (34) 3067 v 1718 vs (1724)calc 1618 vs 1383 m 235
(1624)calc (1367)calc(/C-O (257)calc
8acetyl-C-7oxy-acetH (22) 3071v, 2964vw 1692 s/1760 m – – –
(1739/1780)calc
[Ag(8acetyl-C-7oxy-acet)] (33) 3074v, 2927vw 1721 s (1739)calc 1570 m 1405 m 165
(1578)calc (1375)calc (203)calc
[Ag(8acetyl-C-7oxy-acet)phen2] (44) 3055v 1723 s (1727)calc 1622 s 1400 m (222)
(1622)calc (1352)calc (270)calc
All IR spectra were run as KBr discs. * calculated frequencies with DFT/B3LYP/CB1method, scaled by factor 0.96;
CB1 basis set - see the Computational details.
overl – overlapped, vs – very strong, s – strong, m – medium, w – weak, vw – very weak.
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to 1 × 106 CFU/ml and seeded at 100 μl/well in microtitre well plates.
Bacteriawere also treatedwith a solvent control (0.5%DMSO) in control
wells. Following24h incubation the absorbancewas read in amicrotitre
plate reader. Each compound was screened at each concentration at
least in triplicate and three independent experiments were carried out.
In this study, the ligands, their Ag(I) complexes and 1,10-
phenanthroline adducts were tested for anti-Candida activity using a
broth microdilution susceptibility protocol established by the National
Committee for Clinical Laboratory Standards (NCCLS), document M27-
A2 with slight modifications. The M27-A2 method was altered by
substituting antibiotic medium 3 (Oxoid Ltd.) for RPMI 1640 medium
[60]. All of the test compounds were prepared in 2% DMSO solution as
the compounds were soluble only in DMSO. This solvent system is fre-
quently used for antifungal testing of drugs. However, complexes 35, 36,
41 and42didnot dissolvewell in 2%DMSOand therefore thesewere test-
ed as suspensions. The maximum concentration of the DMSO, after serial
dilution, in the test wells was 0.5%. The inhibitory effect of DMSO on the
growth of C. albicans was also examined and it was shown that 0.5%
DMSO did not affect the growth of this particular strain (ATCC 10231)
of C. albicans. However, the effect of DMSO concentration on the growth
of the Candida species can be dependent on the strain origin and hence
different strains of microbes can have different tolerances to DMSO.
These results indicated that the maximum final concentration of DMSO
that can be used in the assay was ca. 1%. The ligands, complexes and a
commercially available antifungal drug, Amphothericin B were tested
against C. albicans (ATCC 10231). The screeningwas carried out according
to the broth microdilution reference method [60].
2.5. MTT assay
The activity of the ligands and their complexes was assessed using
cancer cell lines: HepG2 cell line, which is a liver-derived cell line, and
A498, which is a renal cell line. Testing was carried out using the
methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay following
96 h exposure of the cells [61]. This method is based on the reduction of
the tetrazolium salt MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetra-
zolium bromide) into a crystalline blue formazan product by the cellular
oxidoreductases of viable cells. The resultant formazan crystal formation
is proportional to the number of viable cells. The following procedure
was used to test the silver complexes andmitoxantrone. Cells were seed-
ed at 4 × 105 cells/ml in 96-well plates and incubated at 37 °C in 5% CO2
for 96 h. Cellswere treatedwith a range of concentrations of the test com-
pounds, in triplicate, from 0.2 to 200 μM or with a solvent control (0.5%
DMSO) in complete medium. After 96 h incubation, the cells were
assayed by the addition of one-tenth (20 μl) of the culture volume with
MTT (5 mg/ml) in 0.1 M phosphate-buffered saline (PBS), pH 7.4, at37 °C in a humid atmosphere with 5% CO2 for 4 h. The medium was
then gently aspirated from test cultures and 100 μl of DMSO was added
to each well. The plates were then shaken for 2 min and the absorbance
was read at 550 nm in a Varioscan plate reader. The IC50 value was de-
fined as the concentration of test compound required to reduce the absor-
bance of the MTT–formazan crystals by 50%, indicating 50% reduction in
cellular activity.2.6. DNA binding studies
The competitive ethidium bromide (EtBr) displacement studies in-
volved the preparation of aworking solution containing 1 μMcalf thymus
DNA (CT-DNA) (ε260 = 12,824 M(bp)−1 cm−1) [bp = base pair] along
with 1.26 μM EtBr at neutral pH in N-[tris(hydroxymethyl)methyl]-2-
aminoethanesulfonic acid (TES) buffer (10 mM TES, 0.10 mM disodium
ethylenediamine tetraacetate (Na2EDTA), pH = 7). Stock solutions of
complex 31 and controls were prepared at 2 mM in 100% DMSO. Two
ml of DNA-Et solution were placed in a 10 mm quartz cuvette (3 ml)
and positioned in a temperature controlled (20 °C) spectrofluorometer.
Excitation and emissionwavelengthswere set to 545 and595nm, respec-
tively. After thermal equilibriumwas established the emission and excita-
tion slitswere changed to give afluorescence reading of 50 arbitrary units
with measurements being recorded over a 20 s interval. An aliquot of
complex or drug solution was taken (1–20 μl), added to the cuvette and
after equilibration the fluorescence reading was recorded. Repeated ali-
quots were added until the fluorescencewas 30–40% of the initial control
or the capacity of the 10 mm quartz cuvette (3 ml) to hold N1000 μl of
sample was exceeded. Triplicate titrations were performed and the
apparent binding constants were calculated using Kapp = Ke × 1.26/
C50 where Ke = 9.50 × 106 M(bp)−1 and 1.26 is the concentration of
EtBr in μM [62].2.7. Determination of nuclease activity
The nuclease activity of complex 31 and controls was determined by
adopting the following method [62]. Reactions were carried out in a
total volume of 20 μl in 0.10 M cacodylate buffer (pH = 6) with 50–
0.50 μM of complex, which were initially prepared in DMF, then diluted
in buffer, with 1 μl of 0.25 μg/μl pBR322DNA (Roche). Sampleswere incu-
bated for 5 h at 37 °C (with and without an added reductant). Quench
buffer (3 μl; 0.25% bromophenol blue, 0.25% xylene cyanole and 30% glyc-
erol)was then added and sampleswere loadedonto agarose gel (1%) con-
taining 1.50 μl/100 ml of solution of GelRedTM (10,000 X).
Electrophoresis was completed at 80 V for 2 h in 1× TAE buffer (Tris-Ac-
etate-EDTA).
Table 4
1HNMRdata for selected ligands, their silver (I) complexes and corresponding phen adducts recorded inDMSO-d6. The calculated chemical shifts forH atoms at B3LYP/6–31+G(d,p) level
are given in parentheses.
1H NMR signals in ppm, peak multiplicity, coupling constants in Hz
Compound H3 H4 H5 H6 H7 H8 H11 \\OH H15 H16 H17
C-3oxy-acetH (12) acet. gp. 7.41 7.60 7.32 7.46 7.38 4.88 13.26
s d td ddd d s
J= 7.7 J= 7.6, 1.1 J = 8.7, 7.3, 1.6 J= 8.1
[Ag(C-3oxy-acet)] (23) acet. gp. 7.08↓ 7.56 7.34 7.34 7.34 4.48
(7.12)a (7.72) (7.67) (7.65) (7.64) (4.66)
s d m s
J= 6.7 J= 14.3, 7.0
[Ag(C-3oxy-acet)phen2] (34) acet. gp. 6.97 7.51 7.30 7.30 7.30 4.28
(7.00) (7.60) (7.66) (7.56) (7.57) (4.28)
s dd m
J= 7.6, 1.3
8acetyl-C-7oxy-acetH (22) 6.35 8.01 7.73 7.09 acet. gp. \\CH3CO 4.91 N/A – 2.55
(6.73) (8.27) (8.07) (7.12) (5.03) (9.33)
(6.57)b (8.31) (8.04) (7.04) (2.74)
d d d d (5.02) (8.29) (2.66)
J = 9.5 J= 9.6 J= 8.8 J= 8.8 s s
[Ag(8acetyl-C-7oxy-acet)] (33) 6.28 7.96 7.64 6.96 acet. gp. \\CH3CO 4.61 N/A – 2.56
(6.42) 7.73 7.99 (6.43) (4.88) (−) (2.88)
(6.30)b (7.82) (7.95) (6.70) (4.90) (2.75)
d d d d s s
J = 9.5 J= 9.6 J= 8.8 J= 8.8
[Ag(8acetyl-C-7oxy-acet)phen2] (44) 6.25 7.97 7.61 6.89 acet. gp. \\CH3CO 4.37 N/A – 2.56
d m d d s s
J = 9.5 J= 8.8 J= 8.8
s= singlet, m=multiplet, d = doublet, dd= doublet of doublets, ddd= doublet of doublet of doublets, acet. gp. (oxy acetic acid group)=\\OCH2COOH, the atom numbering for NMR
signals assignment is given in Table 1.
a The 1H NMR calculations at (B3LYP/6–31 + G(d,p) level) suggested cis-Ag2(C-3oxy-acet)2 structure.
b 1H NMR calculations at B3LYP/6–31++G(2d,p) level of theory for comparison.
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The SOD mimetic activities of the metal complex 31 and controls
were studied by following the change in absorbance atλ=550 nmdur-
ing the reduction of nitroblue tetrazolium (NBT) to blue formazan in the
presence of the tested complex. The assay was run at pH 7.80 in a cu-
vette containing 3 ml of the reaction mixture. The reaction mixture
consisted of a double distilled water solution of 50 μM xanthine,
100 μM NBT and 50 mM PBS. A flux of the superoxide radicals was
established by the addition of 20 μl of diluted xanthine oxidase enzyme
to the cuvette. Reduction of NBT by O2•−was thermostatically controlled
for three minutes at 25 °C and resulted in a 0.02/min change in absor-
bance at λ = 550 nm. This corresponded to a flux of 1 μM O2•−/min.
After the O2•− flux was established, the quantitative reduction of NBT toTable 5
13C NMR data for 2-(2-oxo-2H-chromen-substituted-yl)oxy acetic acids recorded in DMSO-d
B3LYP/6–31 + G(d,p) are given in parenthesis.
13C NMR signals in ppm
Compound C2 C3 C4 C5 C6
C-3oxy-acetH (12) 156.4 142.2 115.1 127.1 124.8
[Ag(C-3oxy-acet)] (23) 156.6 143.1↑ 113.8↓ 126.5 124.4
(156.7)a (140.4) (114.6) (128.4) (119.2)
[Ag(C-3oxy-acet)phen2] (34) 156.9 143.4 113.9 126.6 124.5
(156.9) (140.7) (114.0) (125.0) (120.8)
8acetyl-C-7oxy-acetH (22) 159.4 113.4 144.2 130.3 109.3
(160.1) (109.7) (145.2) (129.5) (106.1)
(161.2)c (110.0) (144.4) (129.2) (106.6)
[Ag(8acetyl-C-7oxy-acet)] (33) 159.3 109.5 144.0 129.7 112.5
(159.9) (107.9) (144.4) (127.4) (109.9)
(160.5)d (108.8) (143.8) (128.5) (110.3)
[Ag(8acetyl-C-7oxy-acet)phen2] (44) 159.7 109.9 144.4 129.8 112.2
Coupling constants in Hz, q = quartet, the atom numbering for NMR signals assignment is giv
a The 13C NMR calculations at (B3LYP/6–31 + G(d,p) level) suggested cis-Ag2(C-3oxy-acet)
b Ref. [70].
c Signals for phen ligands are given in Supplementary material.
d 13C NMR calculations at B3LYP/6–31++G(2d,p) level for comparison.blue formazan by O2•− was followed spectrophotometrically at 550 nm,
in the presence of the tested complex.
3. Results and discussion
3.1. Synthesis and characterisation of silver(I) complexes (23–33) and their
phen adducts (34–44)
Firstly, the ethyl 2-(2-oxo-2H-chromen-substituted-yl)oxy acetate
derivatives (1–11) were prepared by reaction of the appropriate
substituted monohydroxy coumarin with ethyl 2-bromoacetate. Then,
the compounds obtained were used as precursors for the synthesis of 2-
(2-oxo-2H-chromen-substituted-yl)oxy acetic acids (12–22) (Table 1)
by acid hydrolysis in acetone: water (40:60) mixture (Scheme S1 and6 and their corresponding Ag(I) complexes. The calculated chemical shifts for C atoms at
C7 C8 C9 C10 C11 C12 C15 C16 C17
128.8 115.7 149.2 119.5 65.1 169.0 – – –
127.9 115.3 148.8 119.8 67.9↑ 169.6
(126.0) (112.7) (150.3) (119.2) (68.6) (170.5)
127.8 115.5 148.7 120.1 68.5 168.3
(125.5) (112.5) (149.8) (119.5) (69.0) (167.9)
156.8 118.7 150.3 113.1 65.2 169.6 199.0 32.2
155.2) (117.9) (151.3) (113.5) (66.6) (168.4) (206.9) (35.7)
(155.5) (116.8) (150.3) (113.5) (64.8) (170.1) (206.4) (33.5)
158.0 118.5 150.1 112.1 67.9 170.5 198.9 31.9
(156.8) (116.5) 150.4 (111.1) (68.0) (171.2) (206.2) (33.6)
(160.0) (115.6) (149.6) (111.2) (68.6) (172.5) (205.7) (33.3)
158.9 118.3 150.2 111.8 68.6 168.7 199.7 32.1
en in Table S1.
2 structure.
Table 6
Wavelengths of absorptionmaxima (λmax) and extinction coefficient (ε) values for silver(I) complexes (23–33) and their phen adducts (34–44) alongwith the corresponding ligands (12–
22). The calculated vertical excitation energies at TDDFT/B3LYP/CB1 are given for comparison.
Ligand Silver(I) complex Silver(I)-phen adduct
λmax (ε)
nm (M−1 cm−1)
ΔE (osc.str)
nm
Assign λmax (ε)
nm (M−1 cm−1)
ΔE (osc.str)
nm
Assign λmax (ε)
nm (M−1 cm−1)
ΔE (osc.str)
nm
Assign
12 23 34 325 (14080) 325 (0.08) Agsd,L,phen–phen(π*)
310 (14220) 303 (0.44) π-π* 310 (12640) 306 (0.92)*a L(π)-L (π*) 305 (23120) 306 (0.49) L(π)-L(π*)
305 (0.08) L(π)-L (π*) 256 (0.88) phen(π)-phen (π*)
~280 (18220) 285 (0.03) π-π* ~290 283 (0.03) L(π)-L (π*)
235 (0.04) π-π* (11600) 235 (0.15) L(π)-L (π*)
22 320 (17220) 310 (0.54)b π-π* 33 320 (13280) 313 (1.12) L(π)-L (π*) 44 335 (17820)
290 (14780) 284 (0.01) π-π* 285 293 (0.03) L(π)-L (π*)
– – – 265 277 (0.03) L(π)-L (π*)
265 (0.04) L(π)-Agsd,O
240 240 (0.07) π-π* 240 238 (0.12) L(π)-L (π*)
13 320 (5760) 24* 320 (4420) 35 320 (5480)
305 (10680) 305 (8300) 295 (21060)
280 (17080) 280 (11860)
14 325 (5520) 25 325 (5240) 36* 325 (7120)
310 (7540) 310 (7060) 315 (9580)
280 (15080) 285 (9200)
15 340 (4260) 26 350 (3800) 37 345 (4100)
280 (17280) 280 (13360)
16 335 (6360) 27 345 (3940) 38* 340 (4940)
275 (20900) 280 (13720)
17 320 (15400) 28 325 (17120) 39 325 (17540)
18 320 (17560) 29 325 (16460) 40 325 (19720)
285 (13760)
19 315 (15540) 30* 325 (16940) 41 335 (15600)
20 325 (17780) 31 335 (15580) 42* 340 (19320)
21 330 (14200) 32* 345 (13200) 43 345 (15900)
a cis-Ag2(C-3oxy-acet)2; the Ag2(C-3oxy-acet)2 conformers obtained by rotation around Car\\Oacet and C\\C(O2) bonds (producing cis, trans and intermediate conformers) showed the
same UV–Vis spectra.
b Open ligand form as it is shown in Fig. S2.
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spectroscopic data for all ethyl coumarinyloxyacetates (1–11) and cou-
marin oxyacetic acid-based ligands synthesized (12–22) are given in Sup-
plementary material (Tables S1–S4 and S5-S7, respectively).
The reaction methodology for the synthesis of 2-[(2-oxo-2H-chro-
men-substituted-yl)oxy]acetic acid-based silver(I) complexes and its
phen adducts is presented in Scheme 1. The silver(I) complexes (23–
33) were synthesized by deprotonation of the 2-(2-oxo-2H-chromen-
substituted-yl)oxy acetic acid-based ligands (12–22) using a stoichio-
metric amount of sodium hydrogen carbonate and then adding a stoi-
chiometric amount of silver(I) nitrate. Further, the silver(I)-phen
adducts (34–44) were obtained by stirring of the silver(I) complexes
(23–33) with 1,10-phenanthroline in absolute ethanol.Scheme 1. General reaction scheme for the synthesis of 2-[(2-oxo-2H-chromen-3-
yl)oxy]acetic acid-based silver(I) complex and its phen adduct.All of the synthesized silver(I) complexes and their phen adducts
were characterised bymicroanalysis and atomic absorption spectrosco-
py, thermogravimetric analysis, conductivitymeasurements, UV–Vis, IR,
1H and 13C NMR spectroscopies, decomposition temperatures, and in
one case (33), by X-ray diffraction analysis.
Microanalytical and atomic absorption spectroscopic data (Table S8)
revealed that the silver(I) complexes 23–33 have a 1:1 metal-to-ligand
ratio. The silver(I)-phen adducts 34–44 exhibited a 1:1:2 ratio between
metal, ligand and phen, respectively. Complexes 24, 26, 27, 31 and 32
also showed the presence of water molecules and the relative amounts
of water present was determined by thermogravimetric analysis (Fig.
S1, Supplementary material). Unfortunately the addition of the
oxyacetatemoiety to the coumarin nucleus did not increase significant-
ly the solubility of the silver(I) complexes except in the case of complex
[Ag(8acetyl-C-7oxy-acet)] 33, which was sparingly soluble in water at
ambient temperature. More surprisingly, the formation of the phen ad-
ducts, even allowing for the presence of two additional phen ligands in
each silver(I) complex, also did not improve solubilitywith all of the co-
ordination compounds being only soluble in DMSO. The observed con-
ductivity values for the silver(I) complexes and the corresponding phen
adducts at 25 °Cwere in the range 0.43 to 1.95 Scm2mol−1 and at 37 °C
were in the range 1.32 to 2.13 Scm2 mol−1. These values at both tem-
peratures were too low to account for any dissociation of the metal
complexes and adducts in DMSO. Hence, these complexes and their
phen adducts were regarded as non-electrolyte in nature and are con-
sidered to be similar to other coumarin-based complexes [44,63–66].
A number of attemptsweremade to grow crystals suitable for X-ray dif-
fraction analysis for all the silver(I) complexes and their phen adducts
prepared in this study. Unfortunately, crystals could not be obtained ex-
cept for the silver(I) complex [Ag(8acetyl-C-7oxy-acet)] (33).
Fig. 2.Crystal packing diagram for [Ag(8acetyl-C-7oxy-acet)] (33) showing the closestπ-π
interaction.
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Crystal structure data and structure refinement details are given in
Supplementary material (Tables S9-S11). Selected bond lengths and
bond angles are presented in Table 2. The crystal structure, together
with the atom numbering scheme and the crystal packing structure di-
agram are shown in Fig. 1 and Fig. 2, respectively.
There are two unique silver metal centres in 33 but both possess
distorted square pyramidal coordination geometrywith each Ag(I) hav-
ing five contacts within its coordination sphere; four Ag\\O bonds to
four separate coumarin ligands and the fifth contact being to the second
Ag atom with the Ag1-Ag2 separation at 2.749 (15) Å) (see Fig. 1). This
distance is slightly shorter than that in metallic silver (2.88 Å) and sig-
nificantly less than the van derWaals radii for silver (3.44 Å), indicating
the presence of metal-metal interaction [23]. The Ag\\Ag bond is dou-
bly bridged by two carboxylate groups (O14, O15, O28 and O29) with
Ag(I) to syn-syn carboxylate oxygen atoms, distances ranging from
2.126(9) (Ag1-O28) to 2.206(9) Å (Ag2-O29). The Ag-carboxylate
bonds extend to form a column parallel to the a axis via longer Ag\\O
contacts where O29 and O14 make a second longer contact with the
other crystallographically unique Ag atom [Ag2-O14 2.353(8); O29-
Ag1 2.384(9) Å]. The longest and fifth contact to each Ag atom is to
the oxygen of the carboxylic group [Ag1-O16 2.497(11) and Ag2-O2
2.500(10) Å].
The Ag-carboxylate columns lie in an undulating layer sandwiched
between layers of coumarin ligands. The intra-layer aromatic rings of
the coumarin moieties has a centre-to-centre distance of 3.786(2) Å
which is slightly too long for significant π-π interactions. The layer
formed by each coumarin ligand is extended via C\\H⋯O hydrogen
bonds to another coumarin ligand related by a centre of inversion.
This makes a stack of coumarin-AgO-coumarin sandwiches parallel to
the c axis as shown by the crystal packing in Fig. 2. This type of polymer-
ic structure, where one silver ion has contacts with four different cou-
marin ligands, has been previously proposed by our group for
coumarin carboxylate-based silver(I) complexes [21]. Water molecules
build a double column between coumarin ligands forming O\\H⋯O
and C\\H⋯O hydrogen bonds with themselves and the coumarin li-
gands. Crystallographic data for 33 have been deposited at the Cam-
bridge Crystallographic Data Centre, deposition number CCDC 1437900.
3.1.2. Experimental and theoretical infrared spectra
For reliable assignment of the observed IR spectrum of the bridged
binuclear Ag(I) complex (33), molecular structure modeling of
Ag2(8acetyl-C-7oxy-acet)2 (based on the X-ray data) and subsequent
vibrational frequencies calculations were performed, Table 3, Fig. 3.Fig. 1. Crystal structure of [Ag(8acetyl-C-7oxy-acet)] (33) Displacement ellipsoids at the 50% pr
+y, +z; iii 1− x, 1− y, 1− z; iv 3− x, 2− y, 1− z; v 1 + x, +y, +z.For the Ag(I) complexes and their phen adducts with unknown crystal
and molecular structure, the metal-ligand binding modes and some
geometric structure features were predicted on the basis of interpreta-
tion of their experimental and calculated IR spectra. The experimental
and calculated vibrational spectra of selected ligands (12 and 22) and
their Ag(I) complexes (23, 34, and 44) are shown in Figs. S2-S6 (in Sup-
plementary material).
The vibrational analysis of 12, 13 and 22 ligands (representatives of
the 2-(2-oxo-2H-chromen-substituted-yl)oxy acetic acid group)
showed that the first intense band in the 1770–1670 cm−1 region is
due to the acidic carbonyl stretching vibration, ν(C_O)COOH and the
second more intense band is due to the coumarin carbonyl one
(ν(C_O)coum). In some ligands (13, 14, 17) only one intense band
was observed since the two bands mentioned above were overlapped.
The third intense band at 1673 cm−1 in the IR spectrum of 8acetyl-C-
7oxy-acet ligand (22) was attributed to the ν(C_O) vibration of the
acetyl group, Fig. S2.
Upon complexation there were significant changes in the region as-
sociated with stretching vibrations of the carbonyls most likely as a re-
sult of the disappearance of the carboxylic acid functional group from
the region whereas the coumarin carbonyl group appeared slightlyobability level. Symmetry operations to equivalent atoms i 2− x, 2− y, 1− z; ii−1+ x,
Fig. 3. Experimental IR frequencies of Ag(8acet-C-7oxy-acet) (33) complex compared to the calculated (scaling factor 0.96) IR spectrum (at B3LYP/CB1 level) for Ag2(8acet-C-7oxy-acet)2
model (taken from X-ray data for 33).
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frequencies, together with the Δν(OCO) values for the carboxylate
group of the selected silver(I) complexes are listed in Table 3. As evi-
denced by the crystal structure of 33, the primary ligand bonding type
is through carboxylate oxygens to two different Ag(I) centres, which
are involved in oxo-bridge formation, Fig. 1. In addition, the carboxylate
oxygens participate in syn-syn bridge formation with other Ag(I) centre
(weaker bonds). The model calculations of Ag2(8acetyl-C-7oxy-acet)2
and Ag2(C-3oxy-acet)2 species with oxo-bridge simulation reproduce
the main vibrational properties, Fig. 3 and Fig. S5, respectively. The cal-
culated Δν(OCO) values (170–200 cm−1) are in good agreement with
the experimental ones. Hence, the Δν values for the silver(I) com-
pounds (23–33), whichwere in the range 150–205 cm−1 appear typical
for bidentate bridging bonding [67] as evidenced by the spectra ofmany
such complexes including those of 2-(2-oxo-2H-chromen-substituted-
yl)oxy acetic acid ligands in the Ag(I) complexes [68].
Themicroanalytical data for Ag(I)-phen adduct complexes,which sug-
gested an empirical formula of Ag(L)phen2, indicated that the binding
mode of the oxyacetate moiety in these adducts would not be the same
as in the phen freeAg(I) complexes. It is likely that in this case the bonding
of the carboxylate is via an unidentate carboxylate bond as it was found
for the comparable Ag(I) adduct complexes formedwith 4-coumarin car-
boxylate and phenanthroline [33]. The geometry calculations of possible
Ag(8acetyl-C-7oxy-acet)phen2 structures confirmed amonomer silver(I)
complex with N,N-bidentate binding of two phen ligands and a
monodentate bound coumarin oxyacetate ligand through the carboxylicoxygen, Fig. S3, in Supplementary material. The vasym(OCO) and
vsym(OCO) vibrational frequencies for the silver(I)-phen adduct 44were
assigned on the basis of IR frequency calculations. The Δν value was pre-
dicted to be larger as compared to the phen free Ag(I) complex in agree-
ment with the unidentate carboxylate bond (Table 3). The other phen
adducts showed similar spectral behaviour. Unfortunately, we were un-
able to attain a crystal structure for any of the phen adducts. The IR region
1740–1640 cm−1 for the silver(I)-phen adducts 34–44 seems similar to
the corresponding silver(I) complexes (23–33) in line with the presence
of uncoordinated coumarin carbonyl group. The IR spectra of silver(I)-
phen adducts exhibit additional bands at ca. 1420, 840 and 725 cm−1 in-
dicating the presence of 1,10-phenanthroline.
Normally, ν(Ag\\O) stretching vibrations appear in the 280–
250 сm−1 frequency region whereas the ν(Ag\\N) stretching modes
are observed in the 448–362 cm−1 IR and Raman regions [69]. Our vi-
brational frequency calculations predicted that for the bidentate bridg-
ing complexes the ν(Ag\\O) frequency should be at ~380 cm−1. For
Ag(I)-phen adducts (where N,N-bidentate binding of phen ligands and
monodentate binding of coumarinyloxy acetic acid to Ag(I) were pro-
posed) the ν(Ag\\N) frequencies should be at ~400 cm−1 and the
ν(Ag\\O) frequency should appear at ~255 cm−1. However, these
bands do not fall into the measured IR region.
3.1.3. Experimental and theoretical NMR spectra
The formation of silver(I) complexes and their phen adducts in solu-
tion was also predicted and confirmed by NMR spectroscopy. The good
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the Ag(I) complexes 23, 33, 34 (Tables 4 and 5, respectively [70]) con-
firms the bridging bidentate carboxylate binding in Ag(I) complexes
23 and 33 (as it is seen from X-ray analysis of 33) and themonodentate
coumarin carboxylate binding in Ag-phen adduct 34. The atom number-
ing schemeswhichwere used for assignment of 1H and 13C NMR data of
the compounds prepared in this study are given in Table 1. In the 1H
NMR spectra of the silver(I) complexes and their phen adducts, the sig-
nal that corresponded to the carboxylic acid hydrogen at ~13 ppm (for
the coumarin ligand) was absent suggesting that the metal binding is
via the deprotonated carboxylate group. For the complexes prepared,
the 1H NMR signals showed upfield chemical shifts for most of the pro-
tons relative to those of the neutral coumarin ligands. The largest up-
field shift (0.3 ppm) was observed for the methylene protons H11,
which are the closest to the metal binding site, i.e., carboxylate group.
The observed slight upfield shifts (0.1 ppm) of the aromatic 1HNMR sig-
nals are due to a weakening of the π-electron delocalization in the ring
as a result of electron densitywithdrawal to Ag(I), Table 4. The degree of
upfield shifts for H11 and the aromatic hydrogens was greater for the
phen adducts compared to the silver(I) complexes (23–33). The 1H
NMR spectra of the phen adduct 34 have additional signals at ca. 9.15
(Ha), 7.95 (Hb), 8.70 (Hc), 8.15 ppm (Hd), which correspond to the
phen ligands and the relative integration confirmed a 1:2
coumarin:phen ratio. All of these signals had shifted downfield relative
to the corresponding signals in the free phen (9.11, 7.79, 8.50, 8.00 ppm)
[71].
Typically, 13C NMR spectra of 2-(2-oxo-2H-chromen-substituted-
yl)oxy acetic acid-based silver(I) complexes and their phen adducts ex-
hibited downfield chemical shifts relative to the corresponding ligands
(Table 5). The most significant downfield shift observed was for C11
being α to the carboxylate group and near to the complexation site. The
degree of downfield shifts for C11 was greater for the phen adducts com-
pared to the silver(I) complexes (23–33). 13C NMR chemical shifts for
C12 of the carboxylate group, being the coordination site, was also shifted
after complexation as it is observed in the case of substituted coumarin-3-
carboxylatosilver(I) complexes [21]. It should be noted that in case of the
Ag(I) complexes (23–33) the C12 signal is slightly shifted downfield,
whereas in their phen adducts the C12 signal is shifted upfield (by
~1 ppm) as compared to the free ligand. This result could be related to
the different bonding of carboxylate group - bidentate bridging and
monodentate, respectively. Vinylic carbon and aromatic carbons show a
small degree of shielding effect upon complexation. In the 13C NMR spec-
tra of silver(I)-phen adduct34 the phenanthroline peaks at ca. 151.0 (C18),
142.0 (C23) , 138.0 (C20), 129.0 (C21), 127.0 (C22) and 125.0 (C19) ppm
were observed indicating the presence of phenanthroline ligands. Due
to the N,N-coordination of phen to Ag(I) the C18, C20, C19 signals were
downfield shifted relative to free phen (149.9, 136.1, 123.2 ppm),whereas
the C23 is upfield shifted (145.5 ppm for phen). The C21 and C22 signals
were not changed in the Ag(I) complexes. The similarity of the coumarin
and phen signals in the 1H and 13C NMR spectra in solution for the Ag(I)
complexes (23–33) on the one hand and for Ag-phen adducts (34–44)
on the other hand, indicated that the ligandswould appear in an identical
coordination behaviour: bridging bidentate carboxylate binding and
monodentate carboxylate binding of coumarins, respectively and for the
phen adducts the two phen ligands are coordinated to the silver ion
through the two nitrogen donors (Tables 4 and 5).
3.1.4. Experimental and theoretical UV–Vis spectroscopic analysis
TheUV–Vis spectra of the silver(I) complexes and their phen adducts
were compared to the electronic spectra of the corresponding ligands.
The electronic spectral data, i.e., the maximum absorption wavelength
(λmax in nm) and the molar absorptivity (extinction coefficients,
M−1 cm−1) for all of the complexes and phen adducts along with the
corresponding ligands are given in Table 6. TheUV–Vis spectra of select-
ed Ag(I) complexes are shown in the Fig. S7 (in Supplementary materi-
al) and are typical for the spectra obtained for the other coordinationcompounds in this series. The observed UV–Vis spectra of C-3oxy-
acetH (12) and 8acetyl-C-7oxy-acet (22) ligands and their Ag(I) com-
plexes 23, and 33, and the phen adduct 34 were analysed on the basis
of TDDFT/B3LYP/CB1 calculations of the vertical excitation energies in
solution (DMSO) for themodel compounds, Table 6. The TDDFT calcula-
tions of the model ligands 12 and 22 well reproduce the absorption
bands at 310 nm and 280 nm for 12 and at 320, 290 and 240 nm for
22 ligand and they are assigned to 1A(ππ*) excited states (the first
band corresponds to the 21A(ππ*) excited state).
The observed absorption bands at 310, 290 and 240 nm for Ag(I)
complex 23 are due to the ligand L(π)-L(π*) electron transitions and
they are almost unchanged as compared to the ligand (12) absorption
bands. The corresponding Ag(I)-phen adduct 34, however, shows a
new absorption band at 325 nm assigned to the electron transition
from a mixed orbital, involving Ag(sdxy), C-3oxy-acet and phen contri-
butions to phen (π*) orbital.
The typical UV–Vis bands of 8acetyl-C-7oxy-acet appear in the spec-
trum of its Ag(I) complex 33 and they are assigned to L(π)-L(π*) transi-
tions. The intensity of the band at 285 nm is strongly increased in the Ag
complex. A new band at 265 nm appears for the Ag(I) complex 33,
which is attributed to the transition from L(π) orbital to the mixed or-
bital, with Ag(sd), Ocarbox and Oacet contributions. The good agreement
of the experimental and calculated excitation energies confirmed the
suspected structures of the ligands and their Ag(I) complexes in
solution.
In summary, the electronic spectral data of the complexes and phen
adducts exhibited one, two or three bands in the UV region. Typically,
the electronic spectra of silver(I) complexes 23, 26–32 and phen adducts
37–44 exhibited red shifts for at least one of the absorption bands (345
to 280 nm) while [Ag(C-3oxy-acet)phen2] (34) showed a blue shift to
305 nm. However, in some cases no change in energy was observed
compared to the corresponding 2-(2-oxo-2H-chromen-substituted-
yl)oxy acetic acid ligands e.g., [Ag(C-4oxy-acet)] (24) and [Ag(6Cl-C-
4oxy-acet)] (25). The theoretical analysis of selected Ag(I) complexes
23, 34 and 33 (along with the ligands 12 and 22) revealed also an ap-
pearance of new absorption bands in their UV–Vis spectra. For phen ad-
ducts 34–44, an increase in themolar absorptivity values was observed.
This could be due to the presence of multiple organic species (ligand
and phen). All of the silver(I) complexes 23–33 showed a decrease in
the molar absorptivity values compared to the corresponding 2-(2-
oxo-2H-chromen-substituted-yl)oxy acetic acid ligands. The observed
shifts in wavelength (λmax) andmolar absorptivity value may be attrib-
uted to the possibility of polarization of the ligand caused by themetal-
ligand electron interaction [72].
3.2. Determination of antibacterial activities
The MIC50 values, (the concentration of test compound that inhibits
growth by 50% relative to an untreated control) were determined using
methicillin resistant Staphylococcus aureus, MRSA strain, ATCC 4300,
(Manassas, VA, USA) and P. aeruginosa strain, ATCC 27853, as test organ-
isms. Initially, each compoundwas screened using a single independent
broth microdilution experiment in order to shortlist the most active
compounds. Once the most active compounds were identified, they
were tested in triplicate along with a commercially available antibacte-
rial drug, Vancomycin, according to the broth microdilution method
[60].
The results of this set of screening experiments are given in Table 7
as MIC50 values in μM. Complexes 35, 36, 41 and 42were tested as sus-
pensions since theywere not soluble at thefinal concentration of DMSO.
All of the ligands 12–22 were found to be inactive even at the highest
concentration of 100 μMagainst both bacterial strains. TheMIC50 values
of complexes 23–33 against P. aeruginosa ranged from ca. 19 to 36 μM,
indicating the bactericidal potential of these complexes against a resis-
tant Gram-negative strain.Moreover, theywere found to bemore active
than silver(I) nitrate and Vancomycin (Table 7). On the other hand, the
Table 8
Activity of ligands (12–22), silver(I) complexes (23–33) and phen adducts (34–44)-
against C. albicans expressed as MIC50 values.
Compound MIC50 values [(μM± SEM)]
Ligands (12–22) Inactive
Silver(I) complexes 24–26, 29, 30, 32, 33 Inactive
[Ag(C-3oxy-acet)] (23) 91.7 ± 16.5
[Ag(4Me-C-6oxy-acet)].2.2H2O (27) 81.5 ± 17.0
[Ag(C-7oxy-acet)] (28) 79.4 ± 2.2
[Ag(3Cl-4Me-C-7oxy-acet)].0.8H2O (31) 96.7 ± 4.6
[Ag(C-3oxy-acet)phen2] (34) 7.7 ± 0.2
[Ag(C-4oxy-acet)phen2] (35) 11.7 ± 0.3 (susp)
[Ag(6Cl-C-4oxy-acet)phen2] (36) 32.1 ± 0.9 (susp)
[Ag(C-6oxy-acet)phen2] (37) 25.1 ± 0.7
[Ag(4Me-C-6oxy-acet)phen2] (38) 7.5 ± 0.2
[Ag(C-7oxy-acet)phen2] (39) 22.6 ± 0.8
[Ag(4Me-C-7oxy-acet)phen2] (40) 13.2 ± 2.2
[Ag(3,4,8-triMe-C-7oxy-acet)phen2] (41) 58.3 ± 2.4 (susp)
[Ag(3Cl-4Me-C-7oxy-acet)phen2] (42) 35.1 ± 1.0 (susp)
[Ag(4CF3-C-7oxy-acet)phen2] (43) 10.3 ± 0.2
[Ag(8acetyl-C-7oxy-acet)phen2] (44) 9.2 ± 0.5
Silver(I) nitrate (AgNO3) 38.4 ± 2.6
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MIC50 value of silver(I) nitrate but were much higher than that of Van-
comycin, (1.0±0.1 μM). Silver(I) nitrate has amuch higher solubility in
aqueous systems than the complexes tested here. The 1,10-
phenanthroline adducts 34–44 of these complexes also followed the
same trend with the complexes showing higher activity against the
Gram-negative strain and indeed incorporation of 1,10-phenanthroline
molecules into the molecular framework resulted in significantly in-
creased activity as observed from related previous studies [39,73–75].
The silver(I) complexes and their 1,10-phenanthroline adducts dif-
fer in the substituents present on the coumarin nucleus but it was not
possible to correlate the observed activity with any physicochemical
characteristic since within experimental errors, the obtained MIC50
values were found to be comparable with the exception of Ag(8acetyl-
C-7oxy-acet) (33). This increase in the effectiveness of 33 could be at-
tributed to its increased solubility and related bioactivity, induced by
the presence of an acetyl group. Overall, the silver(I) complexes showed
selectivity towards Gram-negative bacteria relative to Gram-positive
bacteria.Dimethyl sulfoxide (DMSO) Inactive
1,10-Phenanthroline 22.5 ± 3.7
Amphotericin B 4.3± 0.43.3. Determination of antifungal activities
In this study, the ligands, their metal complexes and 1,10-
phenanthroline adducts were tested for their anti-Candida activity
using a broth microdilution susceptibility protocol established by the
National Committee for Clinical Laboratory Standards (NCCLS), docu-
ment M27-A2 with slight modifications. The M27-A2 method was al-
tered by substituting antibiotic medium 3 (Oxoid Ltd.) for RPMI 1640
medium [60].
All of the test compoundswere prepared in 2%DMSO solution as this
solvent system is frequently used for antifungal testing of drugs and the
results given in Table 8. Once again, complexes 35, 36, 41 and 42 were
tested as suspensions since theywere not soluble at the final concentra-
tion of DMSO. The maximum concentration of the DMSO, after serialTable 7
Activity of ligands (12–22), silver(I) complexes (23–33) and phen adducts (34–44)-
againstMRSA and P. aeruginosa expressed as MIC50 values.
Compound
MRSA
MIC50 values
[(μM± SEM)]
P. aeruginosa
MIC50 values
[(μM± SEM)]
Ligands (12–22) Inactive Inactive
[Ag(C-3oxy-acet)] (23) 47 ± 12 36.0 ± 0.4
[Ag(C-4oxy-acet)].1.4H2O (24) 41 ± 8 34.7 ± 1.3
[Ag(6Cl-C-4oxy-acet)] (25) 47 ± 12 23.6 ± 0.4
[Ag(C-6oxy-acet)].0.4H2O (26) 49 ± 13 35.7 ± 0.6
[Ag(4Me-C-6oxy-acet)].2.2H2O (27) 47 ± 16 18.9 ± 0.4
[Ag(C-7oxy-acet)] (28) 48 ± 17 19.6 ± 0.6
[Ag(4Me-C-7oxy-acet)] (29) 48 ± 15 32.8 ± 1.7
[Ag(3,4,8-triMe-C-7oxy-acet)] (30) 41 ± 9 23.9 ± 0.4
[Ag(3Cl-4Me-C-7oxy-acet)].0.8H2O (31) 47 ± 15 23.7 ± 0.1
[Ag(4CF3-C-7oxy-acet)].1.5H2O (32) 50 ± 12 31.4 ± 0.7
[Ag(8acetyl-C-7oxy-acet)] (33) 33 ± 1 22.7 ± 0.3
[Ag(C-3oxy-acet)phen2] (34) 17 ± 1 17.6 ± 0.2
[Ag(C-4oxy-acet)phen2] (35) 29 ± 3 (susp) 17.1 ± 0.2 (susp)
[Ag(6Cl-C-4oxy-acet)phen2] (36) 25 ± 1 (susp) 18.0 ± 0.1 (susp)
[Ag(C-6oxy-acet)phen2] (37) 38 ± 1 17.4 ± 0.1
[Ag(4Me-C-6oxy-acet)phen2] (38) 18 ± 0.05 17.0 ± 0.0
[Ag(C-7oxy-acet)phen2] (39) 29 ± 2 17.4 ± 0.1
[Ag(4Me-C-7oxy-acet)phen2] (40) 30 ± 0.5 17.2 ± 0.1
[Ag(3,4,8-triMe-C-7oxy-acet)phen2] (41) 25 ± 3 (susp) 17.5 ± 0.3 (susp)
[Ag(3Cl-4Me-C-7oxy-acet)phen2] (42) 28 ± 6 (susp) 16.7 ± 0.2 (susp)
[Ag(4CF3-C-7oxy-acet)phen2] (43) 16 ± 1 16.9 ± 0.1
[Ag(8acetyl-C-7oxy-acet)phen2] (44) 21 ± 1 17.4 ± 0.1
Silver(I) nitrate (AgNO3) 54 ± 2 51.4 ± 14.1
Dimethyl sulfoxide (DMSO) Inactive Inactive
1,10-Phenanthroline 51 ± 2 Inactive
Vancomycin 1.0 ± 0.1 66.3 ± 2.5dilution, in the test wells was 0.5%, a concentration which was found
to be non-toxic to the tested cells. The ligands, complexes and a com-
mercially available antifungal drug, Amphothericin B were tested
against C. albicans strain ATCC 10231. The metal-free ligands were
found to be inactive as were silver(I) complexes 24–26, 29, 30, 32 and
33. Low anti-Candida activity (79 to 97 μM) was exhibited by silver(I)
complexes 23, 27, 28 and 31.
On the other hand, the adducts formed by these silver(I) complexes
with 1,10-phenanthroline showed significant anti-Candida activity with
most showing better activity than the silver(I) nitrate salt. Complexes
38, 43 and 44 all showed excellent activity (Table 8) comparable to
the benchmark MIC50 values of the commercial drugs Amphotericin B
i.e., 4.3 μM and Ketoconazole i.e. 4.7 μM [75]. It is difficult to suggest a
definitive structure-activity relationship based upon the differences in
physicochemical properties of these complexes given their comparable
antimicrobial activities. The improvement in anti-Candida activity was
expected from the 1,10-phenanthroline adducts of silver(I) complexes
because such improvement in activity is well documented [39,73,74].
Moreover, this activity could also be attributed to the presence of
three structural moieties, the coumarin-derived ligand and two 1,10-
phenanthroline ligands in one molecular frame, which become biologi-
cally active upon coordinating to a metal centre.Table 9
IC50 values (in μM) for tested complexes against human-derived cancer cell lines.
Compound A498
(μM± SEM)
HepG2
(μM± SEM)
All ligands Inactive Inactive
[Ag(C-3oxy-acet)] (23) 64.70 ± 5.10 40.50 ± 4.10
[Ag(C-4oxy-acet)].1.4H2O (24) 64.20 ± 3.70 47.20 ± 3.90
[Ag(6Cl-C-4oxy-acet)] (25) 71.50 ± 11.20 34.30 ± 1.70
[Ag(C-6oxy-acet)].0.4H2O (26) 56.40 ± 1.40 40.10 ± 2.20
[Ag(4Me-C-6oxy-acet)].2.2H2O (27) 60.50 ± 2.90 28.10 ± 4.30
[Ag(C-7oxy-acet)] (28) 55.60 ± 2.70 44.00 ± 2.80
[Ag(4Me-C-7oxy-acet)] (29) Inactive 36.30 ± 3.20
[Ag(3,4,8-triMe-C-7oxy-acet)] (30) 61.00 ± 6.80 24.90 ± 4.70
[Ag(3Cl-4Me-C-7oxy-acet)].0.8H2O (31) 51.40 ± 1.30 29.40 ± 1.80
[Ag(4CF3-C-7oxy-acet)].1.5H2O (32) 58.30 ± 0.5 26.30 ± 5.0
[Ag(8acetyl-C-7oxy-acet)] (33) 63.30 ± 5.50 27.40 ± 1.70
Silver(I) nitrate (AgNO3) 49.80 ± 3.00 32.30 ± 4.00
1,10-Phenanthroline N100 N100
Mitoxantrone 72.70 ± 10.80 38.90 ± 0.40
Fig. 4. Competitive ethidium bromide displacement for pentamidine, 3Cl-4Me-C-7oxy-
acetH (21), silver nitrate and [Ag(3Cl-4Me-C-7oxy-acet)]0.8H2O (31) with CT-DNA
shown up to 200 μM.
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The improved solubility of complex 33, relative to the other silver(I)
complexes, did not result in any increased activity against microbial
cells. A number of previous studies on related complexes had shown
that silver(I) complexes of coumarins were active against immortalised
cell lines [76] and it was thought that the increased solubility of com-
pound 33may give rise to an increase in cytotoxicity against mammali-
an-derived cells. Thus that series of derivatives were screened for their
cytotoxicity against two cell lines, HepG2 cell line, which is a liver-de-
rived cell line, and A498, which is a renal cell line. As can be seen from
Table 9 the cytotoxicities of the complexes were similar to that of silver
nitrate (and indeed comparable to that of the controlmitoxantrone) but
themost soluble complex again did not show any significantly different
activity in comparison to the other complexes. However the complexes
isolated did have significant cytotoxicity as we have recently identified
two series of related complexes, one series based on hydroxynitro-cou-
marin complexes of silver(I) [76] and another series based on silver(I)
dicarboxylates [37], both of which had shown cytotoxicity but whose
mechanism of action seemed to be related to their ability to act as anti-
oxidants, and we were interested to see if that was the case here.3.5. DNA binding properties
Complex 31was chosen for these studies as it had reasonable cyto-
toxicity against both mammalian cell lines and was active against the
bacterial and fungal cell lines tested. Many anti-cancer drugs are
thought to exert their effect though DNA binding ability and though
there are reports of antimicrobial compounds acting by interfering
with DNA synthesis in a bacterial cell [77]. A recent report has shown
that an azolylthioetherquinolone complex, which had excellent activityFig. 5. Relaxation of supercoiled (A) pBR322 DNA [lane (I)] to open DNA (C) or linear circular D
7oxy-acetH (21) [lane (4–6)], copper bis-1,10-phenanthroline [Cu(phen2)] + 2 [lane (7–9)] a
out at 37 °C for 5 h and then analysed by agarose gel electrophoresis.against the two bacterial strains used in these studies, exerted its effect
via intercalation intoMRSA DNA through a copper ion bridge [78]. An-
other paper recently published on bisimidazolium-tagged acridines
showed that these compounds had both anti-bacterial and DNA-bind-
ing ability [79].
To confirm whether the silver complex 31, [Ag(3Cl-4Me-C-7oxy-
acet)]0.8H2O had DNA binding ability, competitive EtBr displacement
experiments were conducted with the complex along with its corre-
sponding ligand, 21, and a known intercalator pentamidine using CT-
DNA over the concentration range of 1 to 1000 μM. Ethidium bound
DNA is highly fluorogenic and in the presence of excess ethidium ion
(Et+), binding regions within the DNA polymer become saturated.
Thus, during competitive displacement, an exogenous reagent must
‘compete’ at the binding sitewith Et+ resulting in a sequential reduction
in fluorescence.
As can be seen from Fig. 4, neither the complex, ligand or silver ni-
trate appears to bind to DNA via intercalation as no displacement of
EtBr was seen. Pentamidine was highly efficient in the displacement of
Et+ bound DNA and, as expected, its apparent binding constant
(Kapp=1.50× 105). The coumarin-derived silver complexwhich exhib-
ited cytotoxicity and antimicrobial activity, did not appear tomediate its
effect through DNA interaction/binding (which can happen through a
number of modes) and therefore are likely to target other sites in the
cell other than DNA.
A number of recent papers highlighted the link between antimicro-
bial activity andDNAbinding and/or nuclease activity suggestingpoten-
tial mechanisms for antimicrobial activity that involve binding and/or
irreversible cleavage of bacterial nucleic acids [80]. The nuclease activi-
ties of the complex and its corresponding ligandwere analysed bymon-
itoring the unwinding of supercoiled pBR322 plasmid DNA (Form A) to
open DNA (Form C) or linear circular (Form B) over a concentration
range of 50–0.50 μM for 5 h without an added reductant (Figs. 5 and
6).The extent of strand scissionwas assessed by agarose gel electropho-
resis and compared to copper bisphenanthroline (positive control).
It can be seen from these figures that neither themetal-free ligand or
the silver(I) complex exhibited self-cleaving of supercoiled (SC) DNA
(Form A). Copper bisphenanthroline partially cleaved SC DNA (Form
A) to open circular OC (Form C) at 50 μM (lane 7). Moreover, neither
complex nor controls cleaved DNA even in the presence of added reduc-
tant (mercaptopropanoic acid) at twice the concentration of the test
compounds (Fig. 6). However, in this case the highest concentrations
(50 μM) of copper bisphenanthroline showed a partial nuclease activity.3.6. SOD mimetic activity
Related silver(I) complexes which have shown good antimicrobial
activity and cytotoxicity and which did not show DNA intercalation or
nuclease activity did show potential to reduce oxidative stress in the
yeast S. cerevisiae or in cell free models [37,76]. The SODmimetic ability
of complex 31was tested for its ability to inhibit the reduction of NBT to
blue formazan by the scavenging of the superoxide radicals, whichwereNA (B), in the absence of a reductant, by silver(I) nitrate (AgNO3) [lane (1–3)], 3Cl-4Me-C-
long with Ag(3Cl-4Me-C-7oxy-acet)]0.0.8H2O (31) [lane (10−12)]. Cleavage was carried
Fig. 6. Relaxation of supercoiled (A) pBR322 DNA [lane (I)] in the presence of a reductant, mercaptopropanioc acid, by silver(I) nitrate (AgNO3) [lane (1–3)], 3Cl-4Me-C-7oxy-acetH (21)
[lane (4–6)], copper bis-1,10-phenanthroline [Cu(phen2)] + 2 [lane (7–9)], and complex [Ag(3Cl-4Me-C-7oxy-acet)]0.0.8H2O (31) [lane (10–12)]. Cleavage was carried out at 37 °C for
5 h and then analysed by agarose gel electrophoresis.
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urate. EC50 values were considered to be the concentration (μM) equiv-
alent to 1 unit of a bovine erythrocyte SOD activity and therefore the
lower the magnitude of EC50, the higher will be the SODmimic activity
of the complex. The free ligand 21 did not exhibit SOD activity but com-
plex 31 did show SOD activity (EC50 = 1.20 ± 0.06 μM), albeit lower
than that of native SOD (EC50 = 0.04 μM), and indeed also higher
than silver(I) nitrate 0.15 ± 0.07 μM. The role of silver(I) complexes in
the redox processes in the cell has been identified by a number of
workers in terms or disruption of mitochondrial function but in more
recent times there have been reports where the SOD activity in cells is
increased in the presence of colloidal silver and that groupposed thehy-
pothesis that up-regulation of the SOD enzymes was occurring as a re-
sult of the presence of the silver [81]. In another study the effect of
silver nanoparticle reduced the antioxidative biomarkers in rats which
were under oxidative stress [82]. The role of silver(I) complexes is
thus under current debate but the activity of the complexes isolated
here, which have antimicrobial, antifungal and cytotoxic effects may
have amechanism of action related to their ability to act as antioxidants
rather than by intercalation or nuclease activity which has been shown
by others in the field as outlined earlier.
4. Conclusions
A range of novel silver(I) complexes of coumarin-derived oxyacetate
ligands and their 1,10-phenanthroline adducts were synthesized and
characterised by both experimental and computational methods. As
only one complex could be isolated in crystalline form the comparison
between the experimental and predicted IR, NMR and UV–Vis data
was necessary to predict and confirm the structure of the other com-
plexes. Polymeric structure was predicted for the Ag(I) complexes
(23–33), where the silver ion has contacts with four different coumarin
ligands and Ag\\Ag bond is doubly bridged by two carboxylate groups.
Whereas for their phen adducts (34–44) a monodentate carboxylate
binding of the coumarin ligand, and N,N-bidentate binding of the two
phen ligands to the silver ion were proposed.
The complexes showed promising results against the tested bacteri-
al strains and may have potential as therapeutic agents againstinfectious diseases. The strain specific inhibitory response of these com-
plexes, observed during this study, could be attributed to the fact that
their mode of action in Gram-negative bacteria is likely to be different
to their mode of action in Gram-positive bacteria. The anti-Candida re-
sults were far more striking with the 1,10-phenanthroline adducts
showing better antifungal activity than the silver(I) salt and were capa-
ble of inhibiting the growth of C. albicans by 50% at a concentration
range of ca. 7 to 10 μM. Thiswas comparable to the efficacy of Ketocona-
zole, a commonly prescribed anti-Candida therapeutic.
The general lack of solubility of the Ag(I) complexes studied may
limit their application to topical infections or as additives in surface pro-
tection technologies. Indeed there are a number of commercially avail-
able products such as Foley catheters etc. which are impregnated with
silver(I) additives. However, one of the derivatives isolated had im-
proved solubility compared to all previous coumarin-based silver(I)
complexes but did not show any enhanced antimicrobial activity. Cyto-
toxicity testing of that series of acetate derivatives against human-de-
rived cell lines also did not reveal any structure activity relationship
(SAR) but did indicate that the complexes had good activity against
the clinically relevant HepG2 andA498 cell lines. Preliminarymechanis-
tic studies using complex 31, [Ag(3Cl-4Me-C-7oxy-acet)]⋅0.8H2O, a
complex which had good antimicrobial, antifungal and cytotoxic activi-
ty, indicated that the complex did not interact with DNA via intercala-
tion, did not have nuclease activity but did have SOD mimetic activity.
This is consistent with other recent findings on related complexes
which indicated that silver(I) complexes may potentiate their activity
though an antioxidative process which disrupts metabolism of the dif-
ferent cell types studied.
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PBS phosphate-buffered saline
MTT methylthiazolyldiphenyl-tetrazolium bromide
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